Vor Biopharma
- Country
- đşđ¸United States
- Ownership
- -
- Employees
- 168
- Market Cap
- $60.8M
- Introduction
Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to provide a single company solution for patients suffering from hematological malignancies. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Cambridge, MA.
Clinical Trials
3
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)⢠Click on a phase to view related trials
Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2025-07-29
- Lead Sponsor
- Vor Biopharma
- Target Recruit Count
- 38
- Registration Number
- NCT05984199
- Locations
- đşđ¸
University of California San Diego Moores Cancer Center, La Jolla, California, United States
đşđ¸Stanford Cancer Institute, Stanford, California, United States
đşđ¸Miami Cancer Institute, Miami, Florida, United States
A Long-term Follow-up Study of Patients Who Received VOR33
- Conditions
- Leukemia, Myeloid, Acute
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2025-07-29
- Lead Sponsor
- Vor Biopharma
- Target Recruit Count
- 10
- Registration Number
- NCT05309733
- Locations
- đşđ¸
University of California San Diego Moores Cancer Center, La Jolla, California, United States
đşđ¸Miami Cancer Institute, Miami, Florida, United States
đşđ¸National Institutes of Health, Clinical Center, Bethesda, Maryland, United States
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS
- Conditions
- Leukemia, Myeloid, AcuteMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2025-07-29
- Lead Sponsor
- Vor Biopharma
- Target Recruit Count
- 67
- Registration Number
- NCT04849910
- Locations
- đşđ¸
University of California San Diego Moores Cancer Center, La Jolla, California, United States
đşđ¸Stanford Cancer Institute, Stanford, California, United States
đşđ¸Miami Cancer Institute, Miami, Florida, United States
News
Vor Biopharma Announces Positive Data and New CD45 ADC Program, Analysts See Significant Upside
⢠Vor Biopharma reported updated Phase 1/2 VBP101 study results showing promising relapse-free survival data in AML/MDS patients, exceeding historical benchmarks. ⢠Initial PK data for VCAR33ALLO demonstrated in vivo expansion at the lowest dose, with dose escalation planned, indicating potential efficacy. ⢠The company is developing a new CD45 ADC program (VADC45) for conditioning regimens, offering a fast path to commercial development and partnership opportunities. ⢠Analysts maintain an Outperform rating with a price target of US$11.00, citing significant upside potential from trem-cel and CD45-based depletion approaches.